At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Engineers have spent decades trying to build metals that do not snap, melt, or grind away under extreme conditions, and for a ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

In the Laser Powder Bed Fusion (LPBF) process, metal powder is selectively melted and solidified layer by layer using a laser ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

A new alloy combines the best of the refractory metals with cutting-edge engineering. Even these extremely tough metals can ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND ...